HRMY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Harmony Biosciences Holdings Inc (HRMY) is not a strong buy for a beginner, long-term investor at this time. The stock faces significant risks due to potential loss of exclusivity for its key drug Wakix, as highlighted by multiple analyst downgrades and reduced price targets. While hedge funds have significantly increased their positions, the financial performance shows declining net income and EPS, which raises concerns about the company's profitability. Additionally, technical indicators are mixed, and there are no strong proprietary trading signals to justify immediate action. A hold strategy is recommended until more clarity on the company's patent situation and financial recovery emerges.
The MACD is positive and expanding, indicating bullish momentum. However, the RSI is neutral at 52.104, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot level of 27.477, with resistance at 28.351 and support at 26.602. Overall, the technical indicators suggest a mixed trend with no strong buy signal.
Hedge funds have significantly increased their positions, with a buying increase of 18208.08% over the last quarter. Additionally, the company has secured agreements that delay generic competition for Wakix until September 2029, providing some medium-term stability.
The company's financial performance in Q4 2025 showed a significant decline in net income (-54.55%) and EPS (-54.12%), raising concerns about profitability. Furthermore, no recent news or congress trading data provides additional support for the stock.
In Q4 2025, revenue increased by 21.12% YoY to $243.78M, but net income dropped by 54.55% YoY to $22.49M. EPS also declined by 54.12% YoY to $0.39, and gross margin slightly decreased to 71.88%. The financial performance indicates revenue growth but significant profitability challenges.
Analysts have a mixed to negative outlook on the stock. UBS, Deutsche Bank, and BofA have all lowered their price targets, with UBS and Deutsche Bank citing risks related to Wakix patents and potential generic competition. The current price targets range from $28 to $50, with most analysts maintaining Neutral or Hold ratings. This reflects uncertainty about the company's future prospects.
